Worries Around Sinopharm Resurface Following Low Antibody Tests
Worries around the Chinese Sinopharm vaccine have resurfaced after insufficient antibody levels were recorded in many people who received both vaccinations in Hungary. While those who defend the vaccine assert that people can still have cell immunity, there is increasing evidence that this is not the case. Those wishing to raise awareness on the issue have joined a Facebook group, sending letters to Prime Minister Viktor Orbán, Chief Medical Officer Cecília Müller, and Hungarian healthcare professionals.
There are more than 3.6 thousand members in the rapidly growing “People Vaccinated with Sinopharm with Negative Laboratory Tests,” closed Facebook group. The purpose of the group is to ensure testing and revaccination if necessary for people who have been vaccinated with the Sinopharm vaccine but have little to no antibodies in their immune system.
Gergely Gulyás shared the number of illnesses and deaths after Hungary's second inoculations, concluding that the numbers support vaccination effectiveness.
US Medical Journal: Sinopharm Effective Against Coronavirus
The Journal of the American Medical Association (JAMA) shared the entire documentation of the Sinopharm vaccine, developed by China National Biotec Group Company (CNBG). The study, overwhelmingly made up of younger, healthy male volunteers, concluded that the vaccine is 72.8 and 78.1 percent effective against the coronavirus.
The long-awaited phase three clinical trials of the Sinopharm vaccine have finally been shared, showing that it is effective. The large scale study involved 40,832 volunteers from the United Arab Emirates, Bahrain, Egypt, and Jordan.
Very Few Elders in Sinopharm Vaccine Clinical Trials
Participants were either given two doses within three weeks or a placebo. Two weeks before their second inoculation, significantly more non-vaccinated people had caught the virus than those who were vaccinated at least once.